Display options
Cite
Zhang J, Li X, Zhu HW, et al. Design, synthesis, and primary activity evaluation of pyrrolidine derivatives as matrix metalloproteinase inhibitors. Drug Discov Ther. 2010;4(1):5-12
Zhang, J., Li, X., Zhu, H. W., Wang, Q., Feng, J. H., Mou, J. J., Li, Y. G., Fang, H., & Xu, W. F. (2010). Design, synthesis, and primary activity evaluation of pyrrolidine derivatives as matrix metalloproteinase inhibitors. Drug discoveries & therapeutics, 4(1), 5-12.
Zhang, J, et al. "Design, synthesis, and primary activity evaluation of pyrrolidine derivatives as matrix metalloproteinase inhibitors." Drug discoveries & therapeutics vol. 4,1 (2010): 5-12.
Zhang J, Li X, Zhu HW, Wang Q, Feng JH, Mou JJ, Li YG, Fang H, Xu WF. Design, synthesis, and primary activity evaluation of pyrrolidine derivatives as matrix metalloproteinase inhibitors. Drug Discov Ther. 2010 Feb;4(1):5-12. PMID: 22491146.
Copy Download .nbib Format: NLM
Share it on

Drug Discov Ther. 2010 Feb;4(1):5-12.

Design, synthesis, and primary activity evaluation of pyrrolidine derivatives as matrix metalloproteinase inhibitors.

Drug discoveries & therapeutics

J Zhang, X Li, H W Zhu, Q Wang, J H Feng, J J Mou, Y G Li, H Fang, W F Xu

Affiliations

  1. Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, China.

PMID: 22491146

Abstract

A series of novel pyrrolidine derivatives was designed, synthesized, and assayed to determine the derivatives' activity against matrix metalloproteinase-2 (MMP-2) and aminopeptidase N (APN)/CD13. Preliminary biological tests showed that most compounds inhibit MMP-2 in a highly selective manner compared to APN. Compounds 9d, 9e, and 9g had better inhibitory activity than LY52 and could be used as lead compounds in the future.

Publication Types